AI Article Synopsis
- Acromegaly and gigantism are primarily caused by growth hormone-secreting pituitary tumors, which can often be treated successfully through surgery, medication, or radiation.
- Some tumors are resistant to standard treatments, labeled as aggressive/refractory, and generally have a worse outlook compared to pituitary carcinomas.
- There is currently no clear method for diagnosing these aggressive tumors, hindering the development of new treatment strategies, but research includes potential markers and therapies for future exploration.
Article Abstract
The majority of acromegaly and gigantism are caused by growth hormone-secreting pituitary neuroendocrine tumors (PitNETs). Most cases can be cured or controlled by surgery, medical therapy, and/or radiotherapy. However, a few of these tumors are resistant to traditional therapy and always have a poor prognosis. The title aggressive/refractory is used to differentiate them from pituitary carcinomas. To date, there is no definitive conclusion on how to diagnose aggressive/refractory growth hormone-secreting PitNETs, which may have slowed the process of exploring new therapeutical strategies. We summarized the literature described diagnosis and treatment of the disease. Potential disease markers and prospective therapies were also included.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368557 | PMC |
| http://dx.doi.org/10.1155/2024/5085905 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-cell and spatial transcriptomic analyses reveal heterogeneity characteristics and specific cell subtype regulators in growth hormone-secreting pituitary adenomas.
Int J Surg
December 2024
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: Growth hormone-secreting pituitary adenomas (GHPA) display diverse biological behaviors and clinical outcomes, necessitating the identification of tumor heterogeneity and prognostically relevant markers.
Methods: In this study, we performed single-cell RNA sequencing (scRNA-seq) on 10 GHPA samples, four of which also underwent spatial transcriptome sequencing, and used scRNA-seq data from four normal pituitary samples as controls. Cell subtype characterization in GHPA was analyzed using multiple algorithms to identify malignant bias regulators, which were then validated using a clinical cohort.
A single-center prospective study evaluating the relationship of tumor consistency on remission in acromegaly patients.
Sci Rep
January 2025
Department of Neurosurgery, Bahcesehir Universty School of Medicine, Istanbul, Turkey.
The nature of somatotroph adenomas has not been clearly revealed in studies. We consider that there are macroscopic differences in intraoperative tumor consistency in acromegaly patients. We aimed to determine whether there is a relationship between intraoperative tumor consistency and histopathological subtypes by planning a prospective study to determine whether these differences are significant.
View Article and Find Full Text PDFDigital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumors.
Eur J Endocrinol
January 2025
Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, 16132 Genova, Italy.
Immunohistochemistry (IHC) of somatostatin receptor subtype 2 can predict response to first-generation somatostatin receptor ligands (fg-SRLs) in acromegaly. Recently, we validated an open-source digital image analysis (DIA) to quantify somatostatin receptor subtype 2 (SSTR2) expression. We aimed to validate the DIA also on somatostatin receptor subtype 5 (SSTR5) in a new cohort of growth hormone (GH)-secreting pituitary tumors, with IHC performed in a different laboratory, and to correlate fg-SRL response with SSTs expression.
View Article and Find Full Text PDFGrowth Hormone-Secreting Pituitary Adenoma: Dura Mater Invasion Is Not a Predictor of Acromegaly Persistence After Trans-Sphenoidal Surgery.
J Clin Med
December 2024
Skull Base and Pituitary Surgery Unit, "Città della Salute e della Scienza" University Hospital, 10126 Turin, Italy.
: In pituitary adenomas, examinations of surgical specimens have shown that dural invasion occurs in 42-85% of cases. No studies about dura mater invasion have been conducted specifically in acromegaly patients. The aim of the present study was to evaluate the relationship between histologically dural invasion and the main features of GH-secreting adenomas.
View Article and Find Full Text PDFDevelopment and characterization of a novel injectable thyroid extracellular matrix hydrogel for enhanced thyroid tissue engineering applications.
Front Bioeng Biotechnol
November 2024
Department of Thyroid and Breast Surgery, Tengzhou Hospital Affiliated to Xuzhou Medical University, Tengzhou, China.
Hypothyroidism, a condition characterized by decreased synthesis and secretion of thyroid hormones, significantly impacts intellectual development and physical growth. Current treatments, including hormone replacement therapy and thyroid transplantation, have limitations due to issues like hormone dosage control and immune rejection. Tissue engineering presents a potential solution by combining cells and biomaterials to construct engineered thyroid tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!